Site-level variation in and practices associated with dabigatran adherence.
about
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyImpact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Transforming the care of atrial fibrillation with mobile health.Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Innovative designs of point-of-care comparative effectiveness trials.Reimagining Anticoagulation Clinics in the Era of Direct Oral AnticoagulantsEfficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence.Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.The Health Buddies App as a Novel Tool to Improve Adherence and Knowledge in Atrial Fibrillation Patients: A Pilot StudyAdherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.Adherence to long-term anticoagulation treatment, what is known and what the future might hold.Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants.Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics.Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants.Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.Patient satisfaction with extended-interval warfarin monitoring.Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.Stroke Risk Stratification in Atrial Fibrillation: Bridging the Evidence Gaps.Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting.Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications.Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality.Effect of a Rivaroxaban Patient Assistance Kit (R-PAK) for Patients Discharged With Rivaroxaban: A Randomized Controlled Trial.Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.Pharmacist Interventions Regarding the Appropriateness of Apixaban, Rivaroxaban, Dabigatran, and Warfarin in a University-Affiliated Outpatient Clinic.A pharmacist checklist for direct oral anticoagulant management: Raising the bar.
P2860
Q26766303-42C5E9DF-B7BA-4748-9420-BEB5E6779FF6Q30994474-51821039-B1CB-46EC-A0A9-662228CB1152Q33449196-42D952F6-7C30-4045-9890-65EE5BF81FADQ34670808-72D66D11-DA27-4B26-A531-2D853960A451Q36264914-79951327-3429-4549-9CD2-E9A2767EA5DDQ36693080-80C13B68-257D-4DF4-9A59-644445B60160Q37649893-6BA67EB7-326D-44CC-865E-C753EDD58BA7Q38630768-22DBFE30-FC20-4B7C-9F34-B8C7A7035831Q38654986-B0E8F4AF-0C07-463C-BCDC-18F9C256BC9DQ38655951-35F371CF-1926-44CF-895C-06C54D45E22EQ38664920-DEDECF9F-CAC4-45A0-A08D-417D992494DFQ38821650-DD96EC25-2B01-4D8F-8FC6-7ECFF9C6DD00Q38833151-C91215EE-A940-4C05-94A5-D0901EB27194Q38895665-550EE41E-A618-4FC4-8726-2288351499EBQ38984971-40C39A1E-80E9-4F77-B203-2ED80DB11F3AQ39041243-E6170047-DBE5-456F-A059-91AD63373F09Q39449914-3EAD7672-3F5F-4762-8A42-C870F27BBBFCQ39456624-92CCD769-93DA-429B-B21C-9FC7C5BA3ACDQ39567501-F44562C7-5C65-4957-AE73-BE3DB8505952Q39717056-565427F1-5CD8-40DE-8E1F-564F12808EBCQ40267269-25E6D723-CFBD-4B34-8AD2-61BF72B9A630Q40668973-FF70E9E9-10CE-489C-AC4F-7EB1606BB265Q44627197-683A0113-664B-4147-82A9-5238C53EDBDEQ47790924-255137EE-3C01-4175-A80F-D65B06FCBF1DQ47803775-A3623A08-3430-400E-9224-DCE146E7A01CQ47989810-202162A3-336A-4DE8-8916-384CD86B9E84Q49546448-FEDF4D5D-F605-4354-BEA8-947122714216Q49587052-D25D089B-5FCB-4178-8E22-4BBB528B9CABQ50193584-68CBBE61-37F0-41F0-B1F2-9F453470556DQ55309883-66F48B21-D4A8-4E8B-BC95-5D3D24A6D7BFQ55401173-89879117-7E7B-42CD-BFE6-CF066FD79FB0
P2860
Site-level variation in and practices associated with dabigatran adherence.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Site-level variation in and practices associated with dabigatran adherence.
@en
type
label
Site-level variation in and practices associated with dabigatran adherence.
@en
prefLabel
Site-level variation in and practices associated with dabigatran adherence.
@en
P2093
P356
P1476
Site-level variation in and practices associated with dabigatran adherence.
@en
P2093
Anne Lambert-Kerzner
Cynthia Jackevicius
Evan P Carey
Fran Cunningham
Lisa Longo
Mintu P Turakhia
P Michael Ho
Supriya Shore
Thomas J Glorioso
P304
P356
10.1001/JAMA.2015.2761
P407
P50
P577
2015-04-01T00:00:00Z